99.5% PURITY LOT VL-2783-A Cagrilintide
A long-acting amylin analogue supplied as a 5 mg lyophilized vial for research into appetite regulation and body-weight control.
- 1 × Cagrilintide 5mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
About this compound
A long-acting amylin analogue supplied as a 5 mg lyophilized vial for research into appetite regulation and body-weight control.
- 5 mg lyophilized peptide per vial
- Long-acting amylin analogue
- Synthetic peptide, ≥99% purity
- Studied in combination with other metabolic peptides
Why the lot matters
- Synthesized and tested per lot, never as a production-run average
- Certificate of Analysis published before the lot goes on sale
- Independent lab, contractually separate from manufacturing
What "research use only" means
This product is sold exclusively for in-vitro laboratory research. It is not evaluated by any medicines agency and is not intended for human or animal administration, diagnosis, treatment, or prevention of disease.
Technical data
Current lot snapshot
Shipping
Reported use in research
Cagrilintide is a long-acting analogue of amylin, a peptide co-secreted with insulin. In animal research it has been studied for obesity and type 2 diabetes, as well as for liver and cardiovascular endpoints. Much research focuses on combining cagrilintide with semaglutide, where the two appear to act synergistically on appetite regulation and body weight.
Reported findings
In research models the combination of cagrilintide and semaglutide (often referred to as CagriSema) produced more robust and durable weight-loss effects than either agent alone. Preclinical studies suggest promising metabolic potential, though human clinical data remain limited and ongoing.
Handling & safety
As an amylin analogue, the most commonly reported research observations are gastrointestinal, including nausea, and are generally dose-dependent. Clinical safety characterization is still emerging and further research is required to define its profile.
Reconstitution
Recommended ratio
- 0.5 mL of bacteriostatic water per 5 mg vial
- Equivalent to 10 mg/mL (i.e. 1 mg per 10 units on a 100 U insulin syringe)
- Remove the plastic flip-off lid from the vial.
- Disinfect the rubber stoppers with alcohol wipes.
- Inject the diluent slowly down the inner wall of the vial to avoid foaming.
- Gently swirl the vial (never shake). Let it dissolve for about 10 minutes.
Storage
Unopened / before reconstitution
- Store at a stable temperature.
- Stable for 24 months.
- For long-term storage (2+ years), store at -20 °C.
Reconstituted solution
- Must be kept refrigerated.
- Avoid exposure to light and excessive heat.
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 4409.01 g/mol | PASS |
| Purity | HPLC (area %) | 99.5% | PASS |
| Net peptide content | Gravimetric | 5.00 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 4409.01 g/mol | PASS |
| Purity | HPLC (area %) | 99.4% | PASS |
| Net peptide content | Gravimetric | 5.01 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 4409.01 g/mol | PASS |
| Purity | HPLC (area %) | 99.7% | PASS |
| Net peptide content | Gravimetric | 5.01 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2783-A | Jul 2026 | 99.5% | TR-88223 | Active | |
| VL-2764-B | May 2026 | 99.4% | TR-88290 | Sold out | |
| VL-2821-C | Mar 2026 | 99.7% | TR-88285 | Sold out |
